NX-1207: A novel investigational drug for the treatment of benign prostatic hyperplasia

Expert Opinion on Investigational Drugs

Volumn 19, Issue 2, 2010, Pages 305-310

  Shore, Neal ^a  

^a Carolina Urologic Research Center   (United States)

Author keywords

Benign prostatic hyperplasia; Enlarged prostate; Lower urinary tract symptoms; Prostate

Indexed keywords

AGENTS ACTING ON THE GENITAL SYSTEM; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CETRORELIX; DEGARELIX; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; GONADORELIN ANTAGONIST; NX 1207; OZARELIX; PLACEBO; SILODOSIN; TADALAFIL; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG;

APOPTOSIS; BLADDER; BLADDER NECK CONTRACTURE; BLEEDING; BREAST AUGMENTATION; CELL LOSS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FLOPPY IRIS SYNDROME; HEMATURIA; HUMAN; HYPONATREMIA; HYPOTENSION; IMPOTENCE; INCONTINENCE; IRIS DISEASE; LIBIDO DISORDER; LOWER URINARY TRACT SYMPTOM; MALE; NONHUMAN; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; PROSTATE SURGERY; RETROGRADE EJACULATION; REVIEW; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; SYNCOPE; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION SYNDROME; URETHRA STRICTURE; URINARY TRACT INFECTION; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; APOPTOSIS; CHOLESTENONE 5 ALPHA-REDUCTASE; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; HUMANS; MALE; MICROWAVES; PROSTATE; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 74549157758     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903555196     Document Type: Review

References (18)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-479
2. Wei JT, Calhoun EA, Jacobsen SJ. Benign prostatic hyperplasia. In: Litwin MS, Saigal CS, editors, Urologic diseases in America. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Office, NIH Publication No. 07-5512, Washington, DC; 2007. p. 48-53
3. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150:85-89
4. American Urological Association, Guideline on the Management of Benign Prostatic Hyperplasia (2003). Available from: http://www.auanet.org/content/ guidelines-and-quality-care/ clinical-guidelines.cfm?sub=bph
5. European Association of Urology, Guidelines on Benign Prostatic Hyperplasia (2004). Available from: http://www.uroweb.org/fileadmin/ tx-eauguidelines/2009/Full/BPH.pdf
6. Roehrborn CG, Currently available treatment guidelines for men with lower urinary tract symptoms, BJU Int 2008;102(Suppl 2):18-23
7. American Urological Association. Results of the treatment outcomes analyses [Chapter 3]. In: Guideline on the management of benign prostatic hyperplasia (BPH). American Urological Association; 2003. p. 3-32-6
8. Lepor H, Rigaud G. The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 1990;143(3):533-537
9. Nichol MB, Knight TK, Wu J, et al. Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 2009;181:2214-21; discussion 2221-2222
10. Verhamme KM, Dieleman JP, Bleumink GS, et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003;44:539-545
11. Nymox Corp., data on file
12. Shore N, Wachs B, Wurzel R, et al. A prospective randomized two dose level comparison of single-injection transrectal intraprostatic NX-1207 and finasteride in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the North Central Section of the American Urological Association; 25 September 2008; Chicago, USA
13. Shore N, Freedman S, Kalota S, et al. Multi-center prospective randomized double-blind study of single-injection transrectal NX-1207 in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the South Central Section of the American Urological Association; 10 September 2007; Boston, USA
14. Cowan B, Cline K, Wachs B, et al. Outcome analysis 8-19 months after single treatment with transrectal NX-1207 in multi-center prospective blinded randomized placebo controlled study of men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the Mid-Atlantic Section of the American Urological Association; 18 October 2007; Bermuda
15. Cowan B, Wachs B, Wurzel R, et al. Prospective randomized phase 2 trial single-injection transrectal intraprostatic NX-1207 in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Annual Meeting of the Western Section of the American Urological Association; 30 October 2008; Monterey
16. Phase 2 Study of NX-1207 for the treatment of benign prostatic hyperplasia. ClinicalTrials.gov Identifier: NCT00759135. Available from: http://clinicaltrials.gov/ct2/show/NCT00759135
17. Clinical evaluation of NX-1207 for the treatment of benign prostatic hyperplasia (BPH) NX02-0017. ClinicalTrials.gov. Identifier: NCT00918983. Available from: http://clinicaltrials.gov/ct2/show/ NCT00918983
18. Clinical Evaluation of NX-1207 for the treatment of benign prostatic hyperplasia (BPH) NX02-0018. ClinicalTrials.gov Identifier: NCT00945490. Available from: http://clinicaltrials.gov/ct2/show/ NCT00945490